Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Aug;25(8):1380–1383. doi: 10.1128/jcm.25.8.1380-1383.1987

Detection of beta-lactamase activity among clinical isolates of Branhamella catarrhalis with six different beta-lactamase assays.

G V Doern, T A Tubert
PMCID: PMC269229  PMID: 3497942

Abstract

A total of 74 different clinical isolates of Branhamella catarrhalis were examined for their ability to produce beta-lactamase by six different beta-lactamase assays. These included a conventional tube and disk test, in which the chromogenic cephalosporin nitrocefin was used as a substrate; a disk procedure, in which pyridinium-2-azo-p-dimethylanaline cephalosporin was used as a substrate; broth and disk acidometric methods; and a conventional tube iodometric assay. A total of 58 of the study isolates produced beta-lactamase. In all cases, positive results were obtained with the nitrocefin tube and disk assays after 1 min. With the pyridinium-2-azo-p-dimethylanaline cephalosporin disk test, 57 of the 58 beta-lactamase-producing strains yielded a positive reaction in 1 min; the remaining strain was positive after 10 min. None of the beta-lactamase-producing strains produced positive reactions by either the broth or disk acidometric methods after 1 min. With the broth test, 10 min was required for positive test results for 42 strains; 30 min was necessary for 16 strains. By the disk acidometric procedure, all 58 strains were positive after 10 min. Of 58 beta-lactamase-producing strains, 30 were positive by the iodometric assay after 1 min, 13 strains required 10 min, and 4 strains were detected as being beta-lactamase positive only after 30 min. One beta-lactamase-producing strain remained negative by the iodometric method. Among the 16 strains of B. catarrhalis that lacked beta-lactamase that were examined in this study, no false-positive results were obtained by any of the six assays.

Full text

PDF
1380

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez S., Jones M., Holtsclaw-Berk S., Guarderas J., Berk S. L. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985 Apr;27(4):646–647. doi: 10.1128/aac.27.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Branhamella catarrhalis. Lancet. 1982 May 29;1(8283):1244–1245. [PubMed] [Google Scholar]
  3. Catlin B. W. Iodometric detection of Haemophilus influenzae beta-lactamase: rapid presumptive test for ampicillin resistance. Antimicrob Agents Chemother. 1975 Mar;7(3):265–270. doi: 10.1128/aac.7.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davies B. I., Maesen F. P. Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in The Netherlands. Drugs. 1986;31 (Suppl 3):28–33. doi: 10.2165/00003495-198600313-00008. [DOI] [PubMed] [Google Scholar]
  5. Doern G. V. Branhamella catarrhalis--an emerging human pathogen. Diagn Microbiol Infect Dis. 1986 Mar;4(3):191–201. doi: 10.1016/0732-8893(86)90098-2. [DOI] [PubMed] [Google Scholar]
  6. Doern G. V., Morse S. A. Branhamella (Neisseria) catarrhalis: criteria for laboratory identification. J Clin Microbiol. 1980 Feb;11(2):193–195. doi: 10.1128/jcm.11.2.193-195.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Doern G. V., Siebers K. G., Hallick L. M., Morse S. A. Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis. Antimicrob Agents Chemother. 1980 Jan;17(1):24–29. doi: 10.1128/aac.17.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Escamilla J. Susceptibility of Haemophilus influenza to ampicillin as determined by use of a modified, one-minute beta-lactamase test. Antimicrob Agents Chemother. 1976 Jan;9(1):196–198. doi: 10.1128/aac.9.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Farmer T., Reading C. Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors. Drugs. 1986;31 (Suppl 3):70–78. doi: 10.2165/00003495-198600313-00015. [DOI] [PubMed] [Google Scholar]
  10. Farmer T., Reading C. beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid. Antimicrob Agents Chemother. 1982 Mar;21(3):506–508. doi: 10.1128/aac.21.3.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jones R. N., Sommers H. M. Identification and antimicrobial susceptibility testing of Branhamella catarrhalis in United States laboratories, 1983-1985. Drugs. 1986;31 (Suppl 3):34–37. doi: 10.2165/00003495-198600313-00009. [DOI] [PubMed] [Google Scholar]
  12. Labia R., Barthelemy M., Le Bouguennec C. B., Buu Hoi-Dang Van A. Classification of beta-lactamases from Branhamella catarrhalis in relation to penicillinases produced by other bacterial species. Drugs. 1986;31 (Suppl 3):40–47. doi: 10.2165/00003495-198600313-00011. [DOI] [PubMed] [Google Scholar]
  13. Luman I., Wilson R. W., Wallace R. J., Jr, Nash D. R. Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production. Antimicrob Agents Chemother. 1986 Nov;30(5):774–776. doi: 10.1128/aac.30.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McLeod D. T., Ahmad F., Power J. T., Calder M. A., Seaton A. Bronchopulmonary infection due to Branhamella catarrhalis. Br Med J (Clin Res Ed) 1983 Nov 12;287(6403):1446–1447. doi: 10.1136/bmj.287.6403.1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ninane G., Joly J., Kraytman M., Piot P. Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid. Lancet. 1978 Jul 29;2(8083):257–257. doi: 10.1016/s0140-6736(78)91763-4. [DOI] [PubMed] [Google Scholar]
  16. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Slevin N. J., Aitken J., Thornley P. E. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet. 1984 Apr 7;1(8380):782–783. doi: 10.1016/s0140-6736(84)91288-1. [DOI] [PubMed] [Google Scholar]
  18. Stobberingh E. E., van Eck H. J., Houben A. W., van Boven C. P. Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis. Drugs. 1986;31 (Suppl 3):23–27. doi: 10.2165/00003495-198600313-00007. [DOI] [PubMed] [Google Scholar]
  19. Sweeney K. G., Verghese A., Needham C. A. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains. Antimicrob Agents Chemother. 1985 Apr;27(4):499–502. doi: 10.1128/aac.27.4.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wilhelmsen L., Berglund G., Elmfeldt D., Samuelsson O., Svardsudd K. The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample. Drugs. 1986;31 (Suppl 1):47–51. doi: 10.2165/00003495-198600311-00009. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES